These data suggest that co-inhibition of PARP and LSS can affect cell viability of tumor cells sensitive to modulation of cholesterol metabolism and that the niraparib-specific target-binding profile, which leads to LSS inhibition, could aid this effect. Here, PARP1 is linked to neoplasm.